1,151 Shares in Stryker Co. (NYSE:SYK) Bought by GAMMA Investing LLC

GAMMA Investing LLC bought a new position in shares of Stryker Co. (NYSE:SYK) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,151 shares of the medical technology company’s stock, valued at approximately $345,000.

Several other institutional investors and hedge funds have also bought and sold shares of SYK. Linden Thomas Advisory Services LLC raised its holdings in Stryker by 13.6% during the fourth quarter. Linden Thomas Advisory Services LLC now owns 3,310 shares of the medical technology company’s stock worth $991,000 after buying an additional 395 shares during the last quarter. Community Bank & Trust Waco Texas purchased a new stake in shares of Stryker in the fourth quarter valued at about $234,000. Parkside Financial Bank & Trust raised its holdings in shares of Stryker by 14.1% in the fourth quarter. Parkside Financial Bank & Trust now owns 827 shares of the medical technology company’s stock valued at $248,000 after purchasing an additional 102 shares during the last quarter. Marks Group Wealth Management Inc raised its holdings in shares of Stryker by 1.1% in the fourth quarter. Marks Group Wealth Management Inc now owns 51,288 shares of the medical technology company’s stock valued at $15,359,000 after purchasing an additional 577 shares during the last quarter. Finally, Larson Financial Group LLC raised its holdings in shares of Stryker by 15.9% in the fourth quarter. Larson Financial Group LLC now owns 10,406 shares of the medical technology company’s stock valued at $3,116,000 after purchasing an additional 1,430 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CAO William E. Berry, Jr. sold 7,690 shares of the stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the sale, the chief accounting officer now directly owns 3,675 shares of the company’s stock, valued at approximately $1,317,414. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the sale, the chief accounting officer now directly owns 3,675 shares of the company’s stock, valued at approximately $1,317,414. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Allan C. Golston sold 3,273 shares of the stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the sale, the director now directly owns 14,242 shares of the company’s stock, valued at $4,856,522. The disclosure for this sale can be found here. In the last ninety days, insiders sold 212,109 shares of company stock valued at $72,845,768. 5.90% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have recently commented on SYK. Wells Fargo & Company increased their target price on shares of Stryker from $336.00 to $364.00 and gave the company an “overweight” rating in a report on Wednesday, January 31st. TD Cowen increased their price target on shares of Stryker from $365.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, April 11th. Canaccord Genuity Group upgraded shares of Stryker from a “hold” rating to a “buy” rating and increased their target price for the stock from $315.00 to $360.00 in a research report on Wednesday, January 31st. Citigroup increased their target price on shares of Stryker from $362.00 to $406.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Finally, Roth Mkm raised their price objective on shares of Stryker from $345.00 to $348.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Three investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $340.67.

Stryker Stock Up 0.6 %

NYSE:SYK opened at $336.85 on Thursday. The firm’s 50-day moving average price is $349.39 and its 200-day moving average price is $314.24. The company has a market capitalization of $128.16 billion, a PE ratio of 40.83, a P/E/G ratio of 2.70 and a beta of 0.89. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.58 and a quick ratio of 0.97. Stryker Co. has a 1-year low of $249.98 and a 1-year high of $361.41.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.27 by $0.19. The business had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The business’s revenue for the quarter was up 11.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.00 EPS. On average, equities analysts predict that Stryker Co. will post 11.86 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be issued a $0.80 dividend. This represents a $3.20 annualized dividend and a yield of 0.95%. The ex-dividend date of this dividend is Wednesday, March 27th. Stryker’s dividend payout ratio is 38.79%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.